Mebendazole

Identification

Summary

Mebendazole is a benzimidazole anthelmintic used to treat helminth infections.

Brand Names
Emverm, Vermox
Generic Name
Mebendazole
DrugBank Accession Number
DB00643
Background

A benzimidazole that acts by interfering with carbohydrate metabolism and inhibiting polymerization of microtubules. [PubChem]

Type
Small Molecule
Groups
Approved, Vet approved
Structure
Thumb
Weight
Average: 295.2927
Monoisotopic: 295.095691297
Chemical Formula
C16H13N3O3
Synonyms
  • (5-benzoyl-1H-benzimidazol-2-yl)-carbamic acid methyl ester
  • MBDZ
  • Mebendazol
  • Mébendazole
  • Mebendazole
  • Mebendazolum
External IDs
  • NSC-184849
  • R 17,635
  • R 17635
  • R-17635

Pharmacology

Indication

For the treatment of Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Mebendazole is a (synthetic) broad-spectrum anthelmintic. The principal mode of action for Mebendazole is by its inhibitory effect on tubulin polymerization which results in the loss of cytoplasmic microtubules.

Mechanism of action

Mebendazole causes degenerative alterations in the tegument and intestinal cells of the worm by binding to the colchicine-sensitive site of tubulin, thus inhibiting its polymerization or assembly into microtubules. The loss of the cytoplasmic microtubules leads to impaired uptake of glucose by the larval and adult stages of the susceptible parasites, and depletes their glycogen stores. Degenerative changes in the endoplasmic reticulum, the mitochondria of the germinal layer, and the subsequent release of lysosomes result in decreased production of adenosine triphosphate (ATP), which is the energy required for the survival of the helminth. Due to diminished energy production, the parasite is immobilized and eventually dies.

TargetActionsOrganism
ATubulin alpha-1A chain
inhibitor
Humans
ATubulin beta-4B chain
inhibitor
Humans
Absorption

Poorly absorbed (approximately 5 to 10%) from gastrointestinal tract. Fatty food increases absorption.

Volume of distribution

Not Available

Protein binding

90-95%

Metabolism

Primarily hepatic. Primary metabolite is 2-amino-5-benzoylbenzimidazole, but also metabolized to inactive hydroxy and hydroxyamino metabolites. All metabolites are devoid of anthelmintic activity.

Hover over products below to view reaction partners

Route of elimination

In man, approximately 2% of administered mebendazole is excreted in urine and the remainder in the feces as unchanged drug or a primary metabolite.

Half-life

2.5 to 5.5 hours (range 2.5 to 9 hours) in patients with normal hepatic function. Approximately 35 hours in patients with impaired hepatic function (cholestasis).

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Acute oral toxicity (LD50): 620 mg/kg [Mouse]. Symptoms of overdose include elevated liver enzymes, headaches, hair loss, low levels of white blood cells (neutropenia), fever, and itching.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
CimetidineThe serum concentration of Mebendazole can be increased when it is combined with Cimetidine.
FosphenytoinThe serum concentration of Mebendazole can be decreased when it is combined with Fosphenytoin.
MethotrexateThe excretion of Methotrexate can be decreased when combined with Mebendazole.
MetronidazoleThe risk or severity of adverse effects can be increased when Mebendazole is combined with Metronidazole.
PhenytoinThe serum concentration of Mebendazole can be decreased when it is combined with Phenytoin.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
  • Take with or without food.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Images
International/Other Brands
Lomper (Esteve) / Meberix (Aversi) / Mebex (Cipla) / Mebezol (Johnson) / Mebfil (Fourrts Laboratories) / Mebutar (Andromaco) / Mebzol (Julphar) / Mendazole (GlaxoSmithKline) / Mezole (Yuan Chou) / Minyoozole (Emil) / Mopen (Li Taka Pharmaceuticals) / Multielmin (Osorio de Moraes) / Necamin (Aché) / Ovex (McNeil) / Panamox (Jayson) / Pantelmin (Janssen) / Tesical (Sintesina) / Thelmox (Remedica) / Ticoquer (Root)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
VermoxTablet100 mgOralJanssen Pharmaceuticals1982-12-31Not applicableCanada flag
VermoxTablet, chewable500 mg/1OralJanssen Pharmaceuticals, Inc.2016-10-20Not applicableUS flag
VermoxTablet, chewable100 mg/1OralJohnson & Johnson Consumer Inc, McNeil Consumer Healthcare Division1975-01-14Not applicableUS flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
EmvermTablet, chewable100 mg/1OralAmedra Pharmaceuticals LLC2016-02-152018-11-30US flag
EmvermTablet, chewable100 mg/1OralAmneal Pharmaceuticals LLC2016-02-15Not applicableUS flag
MebendazoleTablet, chewable100 mg/1Oralbryant ranch prepack2000-06-232017-12-31US flag63629 152820180907 15195 sk1lek
MebendazoleTablet, chewable100 mg/1OralTeva2000-06-232014-05-31US flag0093 910720180907 15195 s37mla
MebendazoleTablet, chewable100 mg/1OralPhysicians Total Care, Inc.1996-04-04Not applicableUS flag00093 9107 29 nlmimage10 8a21c51e
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
CALPO SUSPENSIONSuspensionOralWINWA MEDICAL SDN. BHD.2020-09-08Not applicableMalaysia flag
M-zole Chewable TabletTablet, chewableOralWINWA MEDICAL SDN. BHD.2020-09-08Not applicableMalaysia flag
M-zole SuspensionSuspensionOralWINWA MEDICAL SDN. BHD.2020-09-08Not applicableMalaysia flag
PRIMEDAZOL SUSPENSION 100MG/5MLSuspensionOralPRIME PHARMACEUTICAL SDN. BHD.2020-09-08Not applicableMalaysia flag
PRIMEDAZOL TABLET 100MGTabletOralPRIME PHARMACEUTICAL SDN. BHD.2020-09-08Not applicableMalaysia flag
PRIMEDAZOL TABLET 500MGTabletOralPRIME PHARMACEUTICAL SDN. BHD.2020-09-08Not applicableMalaysia flag
QUEMOX GRANULES 500MGGranuleOralY.S.P. INDUSTRIES (M) SDN BHD2020-09-08Not applicableMalaysia flag
QUEMOX TABLET 500MGTabletOralY.S.P. INDUSTRIES (M) SDN BHD2020-09-08Not applicableMalaysia flag
Royce Mebendazole Tablet 100mgTabletOralROYCE PHARMA MANUFACTURING SDN. BHD.2020-09-08Not applicableMalaysia flag
THELMOX TABLET 100MGTabletOralEUCOGEN SDN BHD2020-09-082020-12-18Malaysia flag

Categories

ATC Codes
P02CA51 — Mebendazole, combinationsP02CA01 — Mebendazole
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzophenones
Direct Parent
Benzophenones
Alternative Parents
2-benzimidazolylcarbamic acid esters / Aryl-phenylketones / Benzoyl derivatives / Imidazoles / Heteroaromatic compounds / Carbamate esters / Organic carbonic acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds
show 2 more
Substituents
2-benzimidazolylcarbamic acid ester / Aromatic heteropolycyclic compound / Aryl ketone / Aryl-phenylketone / Azacycle / Azole / Benzimidazole / Benzophenone / Benzoyl / Carbamic acid ester
show 13 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
carbamate ester, aromatic ketone, benzimidazoles (CHEBI:6704)
Affected organisms
  • Helminthic Microorganisms

Chemical Identifiers

UNII
81G6I5V05I
CAS number
31431-39-7
InChI Key
OPXLLQIJSORQAM-UHFFFAOYSA-N
InChI
InChI=1S/C16H13N3O3/c1-22-16(21)19-15-17-12-8-7-11(9-13(12)18-15)14(20)10-5-3-2-4-6-10/h2-9H,1H3,(H2,17,18,19,21)
IUPAC Name
methyl N-(6-benzoyl-1H-1,3-benzodiazol-2-yl)carbamate
SMILES
COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C1=CC=CC=C1

References

Synthesis Reference

U.S. Patent 3,657,267.

General References
  1. Vermox (Mebendazole) FDA Label [Link]
Human Metabolome Database
HMDB0014781
KEGG Drug
D00368
PubChem Compound
4030
PubChem Substance
46508807
ChemSpider
3890
BindingDB
50180753
RxNav
6672
ChEBI
6704
ChEMBL
CHEMBL685
ZINC
ZINC000000121541
Therapeutic Targets Database
DAP000950
PharmGKB
PA164776669
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Mebendazole
MSDS
Download (72.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentAmoebiasis / Helminthiasis1
4CompletedTreatmentAncylostoma Caninum / Ancylostoma Ceylanicum / Ancylostoma Duodenal / Ascaris Lumbricoides / Ascaris Suum / Necator Americanus / Trichuris Trichiura / Trichuris Vulpis1
4CompletedTreatmentDrug Resistance / Helminths Infection1
4CompletedTreatmentHook Worm1
4CompletedTreatmentHookworm Infections1
4CompletedTreatmentInfection by Trichuris Trichiura1
4CompletedTreatmentIntestinal Diseases, Parasitic / Malnutrition1
4WithdrawnTreatmentHookworm Infections1
3CompletedTreatmentAnemia1
3CompletedTreatmentHealthy Subjects (HS)1

Pharmacoeconomics

Manufacturers
  • Teva pharmaceuticals usa
  • Mcneil pediatrics
Packagers
  • Advanced Pharmaceutical Services Inc.
  • Apotheca Inc.
  • AQ Pharmaceuticals Inc.
  • A-S Medication Solutions LLC
  • Dept Health Central Pharmacy
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • H.J. Harkins Co. Inc.
  • Janssen-Ortho Inc.
  • McNeil Laboratories
  • Novopharm Ltd.
  • Nucare Pharmaceuticals Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Spectrum Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • USAN
Dosage Forms
FormRouteStrength
SuspensionOral2 g
TabletOral100 mg
Tablet, chewableOral500 mg
SuspensionOral2000 mg
TabletOral500 mg
Tablet, chewableOral100 mg/1
Tablet, chewableOral
TabletOral
SuspensionOral
GranuleOral
SuspensionOral20 MG/ML
Tablet, chewableOral500 mg/1
TabletBuccal; Oral100 mg
Tablet, coatedOral300 mg
SuspensionOral100 mg/5mL
Tablet, chewableOral100 mg
Tablet500 mg
Tablet100 mg
Tablet, coatedOral100 mg
Tablet, coatedOral500 mg
Syrup100 mg/5ml
Prices
Unit descriptionCostUnit
Mebendazole 100 mg Chew Tabs16.42USD tab
Mebendazole 100 mg tablet chew5.32USD tablet
Mebendazole powder5.03USD g
Vermox 100 mg Chewable Tablet4.14USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)288.5 °CPhysProp
water solubility71.3 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.83SANGSTER (1994)
logS-3.88ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0387 mg/mLALOGPS
logP2.95ALOGPS
logP3.26ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)8.44ChemAxon
pKa (Strongest Basic)3.93ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area84.08 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity81.5 m3·mol-1ChemAxon
Polarizability31.1 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9932
Blood Brain Barrier+0.9261
Caco-2 permeable+0.7261
P-glycoprotein substrateNon-substrate0.6073
P-glycoprotein inhibitor IInhibitor0.5844
P-glycoprotein inhibitor IIInhibitor0.7534
Renal organic cation transporterNon-inhibitor0.8464
CYP450 2C9 substrateNon-substrate0.749
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6532
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6779
Ames testAMES toxic0.7212
CarcinogenicityNon-carcinogens0.9102
BiodegradationNot ready biodegradable0.994
Rat acute toxicity2.5855 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9515
hERG inhibition (predictor II)Non-inhibitor0.8028
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03dl-0090000000-8828fc1fa56f3c2e418e
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03di-0090000000-024c6803f14cfb0e0114
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03di-0090000000-5d24c800cdbe57cde52a
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03di-0190000000-cc4b2fea662fc4e5f744
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03di-0980000000-6e83d7d5064bd9880802
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-0910000000-b02640332388531fd0fd
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0ar0-0900000000-d45befbb5c042b2c6300
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-016r-2900000000-7e5eb3a1870c7b34c142
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03xr-9600000000-ae4ce30813b2e793a7e7
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03di-0090000000-85dd5a77b566811c09d7
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0090000000-aa34603c660e8b3f4f17
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03dj-0090000000-def7f96fcfca0339b3d1
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0090000000-a66ea36d2742df54240b
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0090000000-b87560a141b5b3d74454
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0890000000-d9b1bed9d118fcec0da6
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0090000000-d291ee80ffb822eea9c1
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0090000000-461e3ef8826b0936ecf3
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03dj-0090000000-0dee2cf61e88f9d5c325
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0090000000-48e3d9d0c50eeb00e28a
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-08fr-1690000000-247931854b864e77c00e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-3920000000-69e5703afaff7dea6bbf
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-6900000000-c4f17560b0011ff9782c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0pdj-9700000000-6972ef1fcc434212d2d4
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0kdj-9400000000-0da6641d46ddb59397f8
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0fb9-9100000000-de684f4cc4c02ad65e77
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03dj-0090000000-ff4e75f9a9b74480c8b5

Targets

Drugtargets2
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
Specific Function
Gtp binding
Gene Name
TUBA1A
Uniprot ID
Q71U36
Uniprot Name
Tubulin alpha-1A chain
Molecular Weight
50135.25 Da
References
  1. Lubega GW, Geary TG, Klein RD, Prichard RK: Expression of cloned beta-tubulin genes of Haemonchus contortus in Escherichia coli: interaction of recombinant beta-tubulin with native tubulin and mebendazole. Mol Biochem Parasitol. 1993 Dec;62(2):281-92. [Article]
  2. MacDonald LM, Armson A, Thompson AR, Reynoldson JA: Characterisation of benzimidazole binding with recombinant tubulin from Giardia duodenalis, Encephalitozoon intestinalis, and Cryptosporidium parvum. Mol Biochem Parasitol. 2004 Nov;138(1):89-96. [Article]
  3. Oxberry ME, Gear TG, Prichard RK: Assessment of benzimidazole binding to individual recombinant tubulin isotypes from Haemonchus contortus. Parasitology. 2001 Jun;122(Pt 6):683-7. [Article]
  4. Ochola DO, Prichard RK, Lubega GW: Classical ligands bind tubulin of trypanosomes and inhibit their growth in vitro. J Parasitol. 2002 Jun;88(3):600-4. [Article]
  5. Wampande EM, Richard McIntosh J, Lubega GW: Classical ligands interact with native and recombinant tubulin from Onchocerca volvulus with similar rank order of magnitude. Protein Expr Purif. 2007 Oct;55(2):236-45. Epub 2007 Apr 25. [Article]
  6. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Unfolded protein binding
Specific Function
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
Gene Name
TUBB4B
Uniprot ID
P68371
Uniprot Name
Tubulin beta-4B chain
Molecular Weight
49830.72 Da
References
  1. Lubega GW, Geary TG, Klein RD, Prichard RK: Expression of cloned beta-tubulin genes of Haemonchus contortus in Escherichia coli: interaction of recombinant beta-tubulin with native tubulin and mebendazole. Mol Biochem Parasitol. 1993 Dec;62(2):281-92. [Article]
  2. MacDonald LM, Armson A, Thompson AR, Reynoldson JA: Characterisation of benzimidazole binding with recombinant tubulin from Giardia duodenalis, Encephalitozoon intestinalis, and Cryptosporidium parvum. Mol Biochem Parasitol. 2004 Nov;138(1):89-96. [Article]
  3. Oxberry ME, Gear TG, Prichard RK: Assessment of benzimidazole binding to individual recombinant tubulin isotypes from Haemonchus contortus. Parasitology. 2001 Jun;122(Pt 6):683-7. [Article]
  4. Ochola DO, Prichard RK, Lubega GW: Classical ligands bind tubulin of trypanosomes and inhibit their growth in vitro. J Parasitol. 2002 Jun;88(3):600-4. [Article]
  5. Wampande EM, Richard McIntosh J, Lubega GW: Classical ligands interact with native and recombinant tubulin from Onchocerca volvulus with similar rank order of magnitude. Protein Expr Purif. 2007 Oct;55(2):236-45. Epub 2007 Apr 25. [Article]
  6. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Baliharova V, Skalova L, Maas RF, De Vrieze G, Bull S, Fink-Gremmels J: The effects of mebendazole on P4501A activity in rat hepatocytes and HepG2 cells. Comparison with tiabendazole and omeprazole. J Pharm Pharmacol. 2003 Jun;55(6):773-81. doi: 10.1211/002235703765951375. [Article]
Kind
Protein group
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...

Components:
References
  1. Baliharova V, Velik J, Savlik M, Szotakova B, Lamka J, Tahotna L, Skalova L: The effects of fenbendazole, flubendazole and mebendazole on activities of hepatic cytochromes P450 in pig. J Vet Pharmacol Ther. 2004 Apr;27(2):85-90. doi: 10.1111/j.1365-2885.2004.00557.x. [Article]

Drug created on June 13, 2005 13:24 / Updated on September 18, 2021 03:33